Reunion Biotech, a Shanghai-based medical hydrogel manufacturer, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B financing round. The funding was led by Dingxin Capital, with existing investors Qiming Venture Partners and Conson Financial Holdings contributing to the oversubscribed round. The proceeds will be allocated towards the regulatory filing and market promotion of the company’s first product, the acceleration of multiple pipeline clinical studies, and the exploration of novel product pipelines.
Reunion Biotech offers systematic solutions for urgent clinical needs, including tumor radiotherapy protection, tumor embolization, and tissue filling, with services spanning across various departments such as radiotherapy, gynecology, urology, and digestive surgery. The company’s flagship product, Respacio, is the first radiation protection hydrogel in China and is being prepared for regulatory filing for the treatment of cervical cancer, following the completion of follow-up from regulatory clinical trials. Respacio has also initiated clinical studies for prostate cancer and pancreatic cancer.- Flcube.com
